Phase 2
18 Years
55 Years
18 Years
55 Years
Open (Enrolling)
Both
Acute Lymphocytic Leukemia
Both
Acute Lymphocytic Leukemia
Trial Information
Inclusion Criteria:
- adult acute lymphocytic leukemia in 1st or second remission
- age 18-55 years
- with inform consent
- no contraindication for allogeneic transplantation: active infection, allergy to
FLu/Bu/CTX, liver and renal function damage
- HLA matched related (6/6) or unrelated donors (at least 8/10)
Exclusion Criteria:
- age less than 18 years or over 56 years
- HLA mismatched related donor
- liver function/renal function damage (over 2 X upper normal range)
- with mental disease
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
overall survival
Outcome Time Frame:
3-year
Safety Issue:
No
Authority:
China: Shanghai JiaoTong University School of Medicine
Study ID:
RJH-ALL-2011
NCT ID:
NCT01435447
Start Date:
April 2011
Completion Date:
April 2014
Related Keywords:
- Acute Lymphocytic Leukemia
- efficacy
- safety
- conditioning
- fludarabine
- busulfan
- cyclophosphamide
- adult
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Name | Location |
|---|
